{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE288nnn/GSE288031/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288031"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Gene expression profiling of 22Rv1 cells treated with a CDK9 degrader, Compound 45 (D45)","description":"As one of the serine/threonine protein kinase family members, Cyclin-dependent kinase 9 (CDK9) functions as a critical regulator of transcription. Its overexpression has been observed in various cancers, including prostate cancer, positioning it as a potential therapeutic target. D45, a newly developed small molecular CDK9 degrader, has been shown to significantly inhibit the growth of triple-negative breast cancer cells. Currently, we carried out a study to explore the role of CDK9 in castration-resistant prostate cancer (CRPC). Hence, human CRPC 22Rv1 cells were treated with small molecule compound, D45, targeting CDK9, followed by RNA-sequencing.","dates":{"publication":"2026/06/27"},"accession":"GSE288031","cross_references":{"GSM":["GSM8757700","GSM8757699","GSM8757702","GSM8757701"],"GPL":["29480"],"GSE":["288031"],"taxon":["Homo sapiens"]}}